{"id":4399097,"date":"2023-10-06T12:34:36","date_gmt":"2023-10-06T17:34:36","guid":{"rendered":"https:\/\/www.olartemoure.com\/?p=4399097"},"modified":"2023-10-06T12:34:46","modified_gmt":"2023-10-06T17:34:46","slug":"first-ever-pharmaceutical-compulsory-license","status":"publish","type":"post","link":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/","title":{"rendered":"First-ever pharmaceutical compulsory license\u00a0"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; theme_builder_area=&#8221;post_content&#8221; _builder_version=&#8221;4.22.2&#8243; _module_preset=&#8221;default&#8221;][et_pb_row _builder_version=&#8221;4.22.2&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; width=&#8221;100%&#8221; custom_padding=&#8221;0px||0px||true|false&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;][et_pb_column _builder_version=&#8221;4.22.2&#8243; _module_preset=&#8221;default&#8221; type=&#8221;4_4&#8243; theme_builder_area=&#8221;post_content&#8221;][et_pb_text _builder_version=&#8221;4.22.2&#8243; _module_preset=&#8221;default&#8221; theme_builder_area=&#8221;post_content&#8221; text_font_size=&#8221;1.2em&#8221; text_line_height=&#8221;1.5em&#8221; hover_enabled=&#8221;0&#8243; sticky_enabled=&#8221;0&#8243;]<\/p>\n<p><a href=\"https:\/\/www.olartemoure.com\/en\/compulsory-license-hiv-aids\/\" target=\"_blank\" rel=\"noopener\">In September, we reported<\/a> that the Interinstitutional Technical Committee (ITC) recommended to the Ministry of Health (MinSalud) to declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing. In this regard, on the second of October of this year, MinSalud issued Resolution 1579, through which it officially adopted the ITC&#8217;s recommendation, confirming that, up to this point, there will be the first compulsory license for a pharmaceutical patent in Colombia.<\/p>\n<p>In this way, MinSalud deemed the arguments against the ITC report presented by several interested third parties as unfounded and, on the other hand, agreed with the reasons given by the CTI, which were: i) alleged increase in HIV\/AIDS cases in the country; ii) the need for the standardization of disease treatment to meet international standards; iii) the need for medical treatment to specific groups; and iv) the reduction of treatment costs.<\/p>\n<p>In its resolution, MinSalud informed the Superintendence of Industry and Commerce that it should initiate the process for granting the respective compulsory license. However, various administrative and judicial mechanisms can be filed against this resolution, such as an appeal for reconsideration, an action for nullity, or a non-compliance action at the level of the Andean Community.<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.<\/p>\n","protected":false},"author":5,"featured_media":4399098,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<!-- wp:divi\/placeholder \/-->","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[51,59],"tags":[],"class_list":["post-4399097","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-patents","category-newsletter-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.4 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>First-ever pharmaceutical compulsory license\u00a0 - OlarteMoure<\/title>\n<meta name=\"description\" content=\"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First-ever pharmaceutical compulsory license\u00a0\" \/>\n<meta property=\"og:description\" content=\"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/\" \/>\n<meta property=\"og:site_name\" content=\"OlarteMoure | Intellectual Property\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-06T17:34:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-06T17:34:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1601\" \/>\n\t<meta property=\"og:image:height\" content=\"837\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nicole Diaz\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicole Diaz\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/\"},\"author\":{\"name\":\"Nicole Diaz\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"headline\":\"First-ever pharmaceutical compulsory license\u00a0\",\"datePublished\":\"2023-10-06T17:34:36+00:00\",\"dateModified\":\"2023-10-06T17:34:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/\"},\"wordCount\":300,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/first-ever-pharmaceutical-compulsory-license.jpg\",\"articleSection\":[\"Patents\",\"Newsletter\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/\",\"name\":\"First-ever pharmaceutical compulsory license\u00a0 - OlarteMoure\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/first-ever-pharmaceutical-compulsory-license.jpg\",\"datePublished\":\"2023-10-06T17:34:36+00:00\",\"dateModified\":\"2023-10-06T17:34:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\"},\"description\":\"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#primaryimage\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/first-ever-pharmaceutical-compulsory-license.jpg\",\"contentUrl\":\"https:\\\/\\\/olartemoure.com\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/first-ever-pharmaceutical-compulsory-license.jpg\",\"width\":1601,\"height\":837,\"caption\":\"first-ever pharmaceutical compulsory license\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/first-ever-pharmaceutical-compulsory-license\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First-ever pharmaceutical compulsory license\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#website\",\"url\":\"https:\\\/\\\/olartemoure.com\\\/\",\"name\":\"OlarteMoure | Intellectual Property\",\"description\":\"Firma especializada en Propiedad Intelectual\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/olartemoure.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/olartemoure.com\\\/#\\\/schema\\\/person\\\/39418ad779f2cd1c62156f11faaf2e31\",\"name\":\"Nicole Diaz\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g\",\"caption\":\"Nicole Diaz\"},\"sameAs\":[\"https:\\\/\\\/www.olartemoure.com\"],\"url\":\"https:\\\/\\\/olartemoure.com\\\/en\\\/author\\\/webmaster\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"First-ever pharmaceutical compulsory license\u00a0 - OlarteMoure","description":"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/","og_locale":"en_US","og_type":"article","og_title":"First-ever pharmaceutical compulsory license\u00a0","og_description":"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.","og_url":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/","og_site_name":"OlarteMoure | Intellectual Property","article_published_time":"2023-10-06T17:34:36+00:00","article_modified_time":"2023-10-06T17:34:46+00:00","og_image":[{"width":1601,"height":837,"url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg","type":"image\/jpeg"}],"author":"Nicole Diaz","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicole Diaz","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#article","isPartOf":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/"},"author":{"name":"Nicole Diaz","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"headline":"First-ever pharmaceutical compulsory license\u00a0","datePublished":"2023-10-06T17:34:36+00:00","dateModified":"2023-10-06T17:34:46+00:00","mainEntityOfPage":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/"},"wordCount":300,"commentCount":0,"image":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg","articleSection":["Patents","Newsletter"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/","url":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/","name":"First-ever pharmaceutical compulsory license\u00a0 - OlarteMoure","isPartOf":{"@id":"https:\/\/olartemoure.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#primaryimage"},"image":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#primaryimage"},"thumbnailUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg","datePublished":"2023-10-06T17:34:36+00:00","dateModified":"2023-10-06T17:34:46+00:00","author":{"@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31"},"description":"To declare the existence of reasons of public interest to subject two Dolutegravir (DGT) patents to compulsory licensing.","breadcrumb":{"@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#primaryimage","url":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg","contentUrl":"https:\/\/olartemoure.com\/wp-content\/uploads\/2023\/10\/first-ever-pharmaceutical-compulsory-license.jpg","width":1601,"height":837,"caption":"first-ever pharmaceutical compulsory license"},{"@type":"BreadcrumbList","@id":"https:\/\/olartemoure.com\/en\/first-ever-pharmaceutical-compulsory-license\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/olartemoure.com\/en\/"},{"@type":"ListItem","position":2,"name":"First-ever pharmaceutical compulsory license\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/olartemoure.com\/#website","url":"https:\/\/olartemoure.com\/","name":"OlarteMoure | Intellectual Property","description":"Firma especializada en Propiedad Intelectual","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/olartemoure.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/olartemoure.com\/#\/schema\/person\/39418ad779f2cd1c62156f11faaf2e31","name":"Nicole Diaz","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6e70a134bc45bb3d433d7aa60e3430b15ff974aaed0e63157795bc7a56800ee8?s=96&d=mm&r=g","caption":"Nicole Diaz"},"sameAs":["https:\/\/www.olartemoure.com"],"url":"https:\/\/olartemoure.com\/en\/author\/webmaster\/"}]}},"_links":{"self":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4399097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/comments?post=4399097"}],"version-history":[{"count":0,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/posts\/4399097\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media\/4399098"}],"wp:attachment":[{"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/media?parent=4399097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/categories?post=4399097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/olartemoure.com\/en\/wp-json\/wp\/v2\/tags?post=4399097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}